Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1988 Oct;58(4):419–422. doi: 10.1038/bjc.1988.233

A comparison of patient survival and tumour growth kinetics in human bronchogenic carcinoma.

K M Kerr 1, D Lamb 1
PMCID: PMC2246795  PMID: 2849973

Abstract

A series of 46 primary bronchogenic carcinomas for which thymidine labelling index (%TLI) (in all cases) and tumour doubling time (DTact) (in 13 cases) had previously been measured were followed up for 5 years and these data compared with length of post operative survival, tumour volume at operation and pathological staging. We found no correlation between reduced survival and higher tumour %TLI, indeed the reverse may be true. Larger tumours tended to have higher labelling indices considering either primary tumour volume or 'T'-category. Five year survivors had smaller tumours, tended to have T1 tumours and Stage I disease but did not have significantly lower tumour %TLIs. No relationship was found between DTact and any other parameter.

Full text

PDF
419

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. COLLINS V. P., LOEFFLER R. K., TIVEY H. Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med. 1956 Nov;76(5):988–1000. [PubMed] [Google Scholar]
  2. Chahinian P. Relationship between tumor doubling time and anatomoclinical features in 50 measurable pulmonary cancers. Chest. 1972 Apr;61(4):340–345. doi: 10.1378/chest.61.4.340. [DOI] [PubMed] [Google Scholar]
  3. Charbit A., Malaise E. P., Tubiana M. Relation between the pathological nature and the growth rate of human tumors. Eur J Cancer. 1971 Aug;7(4):307–315. doi: 10.1016/0014-2964(71)90073-9. [DOI] [PubMed] [Google Scholar]
  4. Friedlander M. L., Hedley D. W., Taylor I. W. Clinical and biological significance of aneuploidy in human tumours. J Clin Pathol. 1984 Sep;37(9):961–974. doi: 10.1136/jcp.37.9.961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hoshino T., Wilson C. B. Cell kinetic analyses of human malignant brain tumors (gliomas). Cancer. 1979 Sep;44(3):956–962. doi: 10.1002/1097-0142(197909)44:3<956::aid-cncr2820440325>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  6. Jackman R. J., Good C. A., Clagett O. T., Woolner L. B. Survival rates in peripheral bronchogenic carcinomas up to four centimeters in diameter presenting as solitary pulmonary nodules. J Thorac Cardiovasc Surg. 1969 Jan;57(1):1–8. [PubMed] [Google Scholar]
  7. Kerr K. M., Lamb D. Actual growth rate and tumour cell proliferation in human pulmonary neoplasms. Br J Cancer. 1984 Sep;50(3):343–349. doi: 10.1038/bjc.1984.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kerr K. M., Robertson A. M., Lamb D. In vitro thymidine labelling of human pulmonary neoplasms. Br J Cancer. 1983 Feb;47(2):245–252. doi: 10.1038/bjc.1983.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lamb D. Histological classification of lung cancer. Thorax. 1984 Mar;39(3):161–165. doi: 10.1136/thx.39.3.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lipford E. H., 3rd, Eggleston J. C., Lillemoe K. D., Sears D. L., Moore G. W., Baker R. R. Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung. Am J Surg Pathol. 1984 May;8(5):357–365. doi: 10.1097/00000478-198405000-00004. [DOI] [PubMed] [Google Scholar]
  11. MARTINEZ C., MIROFF G., BITTNER J. J. Effect of size and/or rate of growth of a transplantable mouse adenocarcinoma on lung; metastasis production. Cancer Res. 1956 May;16(4):313–315. [PubMed] [Google Scholar]
  12. Malaise E. P., Chavaudra N., Tubiana M. The relationship between growth rate, labelling index and histological type of human solid tumours. Eur J Cancer. 1973 Apr;9(4):305–312. doi: 10.1016/0014-2964(73)90099-6. [DOI] [PubMed] [Google Scholar]
  13. Meyer J. A. Growth rate versus prognosis in resected primary bronchogenic carcinomas. Cancer. 1973 Jun;31(6):1468–1472. doi: 10.1002/1097-0142(197306)31:6<1468::aid-cncr2820310623>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  14. Meyer J. S., Hixon B. Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices. Cancer Res. 1979 Oct;39(10):4042–4047. [PubMed] [Google Scholar]
  15. Steele J. D., Buell P. Asymptomatic solitary pulmonary nodules. Host survival, tumor size, and growth rate. J Thorac Cardiovasc Surg. 1973 Jan;65(1):140–151. [PubMed] [Google Scholar]
  16. Steele J. D., Kleitsch W. P., Dunn J. E., Jr, Buell P. Survival in males with bronchogenic carcinomas resected as asymptomatic solitary pulmonary nodules. Ann Thorac Surg. 1966 May;2(3):368–376. doi: 10.1016/s0003-4975(10)66591-5. [DOI] [PubMed] [Google Scholar]
  17. WOOD J. S., Jr, HOLYOKE E. D., CLASON W. P., SOMMERS S. C., WARREN S. An experimental study of the relationship between tumor size and number of lung metastases. Cancer. 1954 May;7(3):437–443. doi: 10.1002/1097-0142(195405)7:3<437::aid-cncr2820070305>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  18. Weiss W., Boucot K. R., Cooper D. A. Growth rate in the detection and prognosis of bronchogenic carcinoma. JAMA. 1966 Dec 19;198(12):1246–1252. [PubMed] [Google Scholar]
  19. Weiss W., Boucot K. R., Cooper D. A. Survival of men with peripheral lung cancer in relation to histologic characteristics and growth rate. Am Rev Respir Dis. 1968 Jul;98(1):75–86. doi: 10.1164/arrd.1968.98.1.75. [DOI] [PubMed] [Google Scholar]
  20. Weiss W. Peripheral measurable bronchogenic carcinoma. Growth rate and period of risk after therapy. Am Rev Respir Dis. 1971 Feb;103(2):198–208. doi: 10.1164/arrd.1971.103.2.198. [DOI] [PubMed] [Google Scholar]
  21. Weiss W. The mitotic index in bronchogenic carcinoma. Am Rev Respir Dis. 1971 Oct;104(4):536–543. doi: 10.1164/arrd.1971.104.4.536. [DOI] [PubMed] [Google Scholar]
  22. Weiss W. Tumor doubling time and survival of men with bronchogenic carcinoma. Chest. 1974 Jan;65(1):3–8. doi: 10.1378/chest.65.1.3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES